DIR fees explained: the definition, mechanics, and 2026 reforms

If you run an independent pharmacy, DIR fees are probably one of the three financial factors that most directly affect your operation — alongside reimbursement rates and dispensing volume. And yet the category itself is often poorly defined, even in PBM communications that are supposed to explain it. This article provides a clean definition, walks through the specific mechanics, and addresses what the 2022 reforms actually changed.

The definition

A Direct and Indirect Remuneration fee — DIR fee for short — is any price concession, rebate, administrative fee, or performance-based adjustment that affects the final net price of a prescription drug, assessed by a Pharmacy Benefit Manager after the original claim is paid. The word "direct" refers to adjustments made by the PBM. The word "indirect" refers to adjustments that flow through other channels, including manufacturer rebates shared with plans.

The regulatory origin of DIR fees is Medicare Part D, where CMS requires plan sponsors to report any remuneration that affects the net cost of prescription drugs under the plan. The reporting was intended to give CMS accurate data about the actual cost of the Medicare drug benefit, so it could calibrate the program appropriately. Over time, PBMs expanded the category from a reporting mechanism into a retroactive fee structure.

The four types of DIR fees you'll actually see

On a given quarterly statement, your DIR fees will typically fall into four structural categories, though the PBM may or may not label them clearly:

Flat network participation fees. A fixed per-claim or per-period fee assessed against all claims under a specific PBM network. These are simple to model and generally the smallest category.

Percentage-of-ingredient-cost fees. A percentage calculated against the ingredient cost of each eligible claim. The percentage typically ranges from about 1.5% to 5% in 2026, depending on the plan and PBM.

Performance-based fees. Variable fees tied to pharmacy-level quality metrics including medication adherence rates, generic dispensing percentages, and CMS Star Rating components. Pharmacies that perform below specified benchmarks pay higher fees.

Reconciliation fees. Retroactive true-up assessments that reconcile what the PBM actually earned from Medicare Part D plans against what was projected or estimated at the time of claim processing. These are often the largest single component on annual DIR statements.

The 2022 point-of-sale reform

In May 2022, CMS finalized a rule that required, effective January 1, 2024, all pharmacy price concessions be reflected in the negotiated price at the point of sale. The rule was widely reported as "the end of retroactive DIR fees" — but the reality is more nuanced.

The rule accomplished two specific things. First, it changed how pharmacy price concessions affect patient cost-sharing. Previously, patients paid cost-sharing based on the higher "pre-concession" price, and the concession was reconciled later. After the rule, patients pay cost-sharing on the lower "post-concession" price, which helps patient affordability. Second, it required plans to include expected pharmacy price concessions in the point-of-sale negotiated price, rather than applying them later.

What the rule did not do is eliminate performance-based DIR fees or other retroactive assessments. PBMs responded to the rule by restructuring more of their fee apparatus into performance-based categories that remain assessable after dispensing. The effect on pharmacies has been mixed — some fee structures were simplified or eliminated, but overall DIR exposure did not decrease significantly, and in some categories it increased.

The 9% figure

You may have seen the statistic that DIR fees can reach 9% of gross Medicare Part D dispensing revenue for independent pharmacies. This figure comes from analyses conducted by the Community Oncology Alliance and other industry groups. It represents the upper bound of observed effective DIR rates, not a typical rate or a cap.

For a pharmacy with $2 million in annual Medicare Part D dispensing revenue, a 9% effective DIR rate translates to $180,000 in annual fee exposure, generally spread across quarterly or semi-annual reconciliation cycles. The actual effective rate at most pharmacies is lower, but the variability is substantial — and for pharmacies that serve high-acuity patient populations with adherence challenges, rates can approach the upper bound.

Why performance metrics are so consequential

After the 2022 reform, performance-based DIR fees became the dominant retroactive mechanism. This matters because performance metrics are largely outside your direct operational control. Patient adherence is driven by patient behavior, insurance formulary dynamics, and prescriber habits. Your pharmacy can counsel, reminder-call, and synchronize — but the measured adherence rate reflects what patients actually do.

When DIR fees scale with performance metrics the pharmacy cannot fully control, the economic exposure becomes something like operational insurance for patient-population risk. Pharmacies that serve adherent, stable patient populations pay lower fees. Pharmacies that serve more medically complex, less adherent populations pay higher fees — even when those pharmacies are providing more intensive clinical care.

Managing DIR exposure

Three practical steps matter at the operational level. First, review your quarterly DIR statements with attention to the breakdown by category — not just the total. The breakdown tells you which mechanisms are driving the bulk of the exposure. Second, track your pharmacy-level adherence metrics and understand how they compare to peer benchmarks. Performance-based fees are where pharmacy action can meaningfully affect exposure, though not always quickly. Third, understand the specific performance-based clauses in each of your PBM provider manuals. The thresholds and methodologies vary significantly, and decisions about network participation can look different when you understand the fee structures explicitly.

For deeper treatment of the clawback mechanics and how the 9% figure compounds across different fee categories, see our longer analysis of DIR fee mechanics.